Identification of B-Amyloid Precursor Protein Ligands
About the Research Project
Program
Award Type
Standard
Award Amount
$200,000
Active Dates
April 01, 2003 - March 31, 2005
Grant ID
A2003076
Summary
Alzheimer’s disease is considered by some to be caused by brain deposits of amyloid beta (Aß) protein plaques. These plaques are formed by the accumulation of a toxic molecule called Aß peptides. This peptide originates from the cleavage of amyloid precursor protein (APP) by proteolytic enzymes called secretases. Understanding the factor(s) that are instrumental in initiating the APP cleavage cascade would be important for the development of drugs to prevent and treat this disease. An APP ligand that can regulate the processing of APP could be a major therapeutic target. It is hoped that modulators of this interaction, once discovered, might be used to create safe and specific Alzheimers disease drugs with limited toxic side effects.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD